Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602801108> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2602801108 endingPage "2550" @default.
- W2602801108 startingPage "2550" @default.
- W2602801108 abstract "2550 Background: ModraDoc001 is a novel oral formulation containing docetaxel as a solid dispersion. Oral administration of docetaxel is feasible in combination with the CYP3A4 inhibitor ritonavir. Objectives were to determine the safety, maximum tolerated dose (MTD) and pharmacokinetics (PK) of weekly oral docetaxel (as ModraDoc001) in combination with ritonavir. Methods: Patients with advanced solid tumors, WHO PS ≤ 2, no concomitant use of MDR or CYP3A modulating drugs, adequate bone marrow (ANC ≥ 1.5x10 9 /L), liver (bilirubin ≤ 1.5xULN, ALAT/ASAT ≤ 2.5xULN) and renal function (creatinine ≤ 1.5xULN or clearance ≥ 50 ml/min) were eligible. Docetaxel (ModraDoc001 10mg capsule) and ritonavir (Norvir 100mg) were simultaneously given once weekly in a ‘3+3 cohort’ dose escalation design. MTD was defined as the highest dose resulting in <1/6 probability of causing a dose limiting toxicity in the first 4 weeks of treatment. This cohort was expanded with 6 patients. PK was determined on days 1 and 8. Results: 40 patients (25 male, 35 evaluable for safety) were enrolled in 6 dose levels (30/100, 40/100, 60/100, 80/100, 60/200 and 80/200 mg docetaxel/ritonavir). Common treatment related adverse events in the 4 highest dose levels were diarrhea (68%), nausea (62%) and fatigue (62%), mostly CTC grade 1-2 (80%, 95% and 73% respectively). Five patients experienced a DLT (grade 3 diarrhea (4), elevated ASAT/ALAT (1), grade 4 dehydration and grade 3 mucositis (1), grade 3 fatigue (2)). The MTD was 60 mg/200 mg docetaxel/ritonavir. Partial remission was seen in 4 patients (CUP, NSCLC, gastric and mamma ca) and sustained stable disease in 15 patients (6x NSCLC). Both drugs were rapidly absorbed after oral administration. Mean Tmax was 2.0 hours (CV=73%) for docetaxel. Cmax and AUC of docetaxel increased less than proportionally with dose to 162 ng/ml (CV= 67%) and 1615 ng/ml*hr (CV= 81%), respectively, in 15 patients at the MTD. Conclusions: At the MTD (once weekly 60 mg docetaxel and 200 mg ritonavir) ModraDoc001 is safe, well tolerated and shows encouraging antitumor activity. The exposure of docetaxel with this regimen is comparable to weekly intravenous administration of 35 mg/m 2 docetaxel. Phase II studies in solid tumors are planned." @default.
- W2602801108 created "2017-04-07" @default.
- W2602801108 creator A5000418012 @default.
- W2602801108 creator A5010531755 @default.
- W2602801108 creator A5027701365 @default.
- W2602801108 creator A5029579710 @default.
- W2602801108 creator A5030111917 @default.
- W2602801108 creator A5038016851 @default.
- W2602801108 creator A5041259777 @default.
- W2602801108 creator A5053650233 @default.
- W2602801108 creator A5056917101 @default.
- W2602801108 creator A5057962780 @default.
- W2602801108 creator A5060207753 @default.
- W2602801108 creator A5062227574 @default.
- W2602801108 creator A5069855324 @default.
- W2602801108 creator A5085958205 @default.
- W2602801108 date "2012-05-20" @default.
- W2602801108 modified "2023-10-01" @default.
- W2602801108 title "Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors." @default.
- W2602801108 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.2550" @default.
- W2602801108 hasPublicationYear "2012" @default.
- W2602801108 type Work @default.
- W2602801108 sameAs 2602801108 @default.
- W2602801108 citedByCount "9" @default.
- W2602801108 countsByYear W26028011082013 @default.
- W2602801108 countsByYear W26028011082015 @default.
- W2602801108 countsByYear W26028011082019 @default.
- W2602801108 countsByYear W26028011082022 @default.
- W2602801108 crossrefType "journal-article" @default.
- W2602801108 hasAuthorship W2602801108A5000418012 @default.
- W2602801108 hasAuthorship W2602801108A5010531755 @default.
- W2602801108 hasAuthorship W2602801108A5027701365 @default.
- W2602801108 hasAuthorship W2602801108A5029579710 @default.
- W2602801108 hasAuthorship W2602801108A5030111917 @default.
- W2602801108 hasAuthorship W2602801108A5038016851 @default.
- W2602801108 hasAuthorship W2602801108A5041259777 @default.
- W2602801108 hasAuthorship W2602801108A5053650233 @default.
- W2602801108 hasAuthorship W2602801108A5056917101 @default.
- W2602801108 hasAuthorship W2602801108A5057962780 @default.
- W2602801108 hasAuthorship W2602801108A5060207753 @default.
- W2602801108 hasAuthorship W2602801108A5062227574 @default.
- W2602801108 hasAuthorship W2602801108A5069855324 @default.
- W2602801108 hasAuthorship W2602801108A5085958205 @default.
- W2602801108 hasConcept C112705442 @default.
- W2602801108 hasConcept C126322002 @default.
- W2602801108 hasConcept C142462285 @default.
- W2602801108 hasConcept C197934379 @default.
- W2602801108 hasConcept C203014093 @default.
- W2602801108 hasConcept C2776694085 @default.
- W2602801108 hasConcept C2778496288 @default.
- W2602801108 hasConcept C2779298103 @default.
- W2602801108 hasConcept C2780580376 @default.
- W2602801108 hasConcept C2781190966 @default.
- W2602801108 hasConcept C29730261 @default.
- W2602801108 hasConcept C2993143319 @default.
- W2602801108 hasConcept C3013748606 @default.
- W2602801108 hasConcept C71924100 @default.
- W2602801108 hasConcept C90924648 @default.
- W2602801108 hasConcept C98274493 @default.
- W2602801108 hasConceptScore W2602801108C112705442 @default.
- W2602801108 hasConceptScore W2602801108C126322002 @default.
- W2602801108 hasConceptScore W2602801108C142462285 @default.
- W2602801108 hasConceptScore W2602801108C197934379 @default.
- W2602801108 hasConceptScore W2602801108C203014093 @default.
- W2602801108 hasConceptScore W2602801108C2776694085 @default.
- W2602801108 hasConceptScore W2602801108C2778496288 @default.
- W2602801108 hasConceptScore W2602801108C2779298103 @default.
- W2602801108 hasConceptScore W2602801108C2780580376 @default.
- W2602801108 hasConceptScore W2602801108C2781190966 @default.
- W2602801108 hasConceptScore W2602801108C29730261 @default.
- W2602801108 hasConceptScore W2602801108C2993143319 @default.
- W2602801108 hasConceptScore W2602801108C3013748606 @default.
- W2602801108 hasConceptScore W2602801108C71924100 @default.
- W2602801108 hasConceptScore W2602801108C90924648 @default.
- W2602801108 hasConceptScore W2602801108C98274493 @default.
- W2602801108 hasIssue "15_suppl" @default.
- W2602801108 hasLocation W26028011081 @default.
- W2602801108 hasOpenAccess W2602801108 @default.
- W2602801108 hasPrimaryLocation W26028011081 @default.
- W2602801108 hasRelatedWork W1987131396 @default.
- W2602801108 hasRelatedWork W2000200648 @default.
- W2602801108 hasRelatedWork W2004439498 @default.
- W2602801108 hasRelatedWork W2021250530 @default.
- W2602801108 hasRelatedWork W2026738950 @default.
- W2602801108 hasRelatedWork W2073728815 @default.
- W2602801108 hasRelatedWork W2135644280 @default.
- W2602801108 hasRelatedWork W2250141976 @default.
- W2602801108 hasRelatedWork W2980223320 @default.
- W2602801108 hasRelatedWork W4240779380 @default.
- W2602801108 hasVolume "30" @default.
- W2602801108 isParatext "false" @default.
- W2602801108 isRetracted "false" @default.
- W2602801108 magId "2602801108" @default.
- W2602801108 workType "article" @default.